A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease - Wikidata - wikimedia - TriplyDB

A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease

A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease

http://www.wikidata.org/entity/Q34070770

about

MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma Diagnostic and therapeutic management of hepatocellular carcinoma Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field.4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics.MicroRNA profile of hepatic epithelioid hemangioendothelioma: A case report.Circulating RNA molecules as biomarkers in liver disease.Serum interferon-related microRNAs as biomarkers to predict the response to interferon therapy in chronic hepatitis C genotype 4 Potential epigenetic mechanism in non-alcoholic Fatty liver disease Associations of circulating plasma microRNAs with age, body mass index and sex in a population-based study.Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection.Circulating microRNAs in nonalcoholic fatty liver disease.Circulating Organ-Specific MicroRNAs Serve as Biomarkers in Organ-Specific Diseases: Implications for Organ Allo- and Xeno-Transplantation miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study Circulating ECV-Associated miRNAs as Potential Clinical Biomarkers in Early Stage HBV and HCV Induced Liver Fibrosis Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.The future of diagnosing NASH - could a simple blood test be the key?Role of MicroRNAs in NAFLD/NASH.Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease.miRNAs in non-alcoholic fatty liver disease.A micro-RNA expression signature for human NAFLD progression miRNA Profiles of Tubular Cells: Diagnosis of Kidney Injury.An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection.miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway.Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity.Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD).To die or not to die: death signaling in nonalcoholic fatty liver disease.Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus

P2860

Q26751392-C34B7FF9-EDD7-4F32-AAFE-8F7B8047ECD5 Q26765476-CA0A24F8-4E50-45BA-BFC3-0D77708CCC8A Q26767346-61B4F713-3ADD-429E-9637-CF7501DE6B14 Q26999043-95D37ABA-EF29-4446-991E-F1066AC0484E Q30400120-AC3BA374-07B2-4E16-BCDC-A2C8917CF8BC Q30412771-236A399A-5AFC-4F15-94D7-8CCB0A550BBE Q33597934-BBD7695F-BED0-477E-98A1-E0F5B7EFF5A6 Q34486635-401B68B0-7CD2-40F2-9D16-E2AED55F7C7F Q35196062-9446B8C8-C308-4007-826E-B92E994EAEAC Q35380845-9FF9719B-A56F-4317-9859-1EB7E2246D00 Q35805098-F084D5D5-41EC-4D0D-8F46-8B2D2FB0C05C Q35840874-CF76FB77-1AE8-4AC7-A078-A064D827CA26 Q36298211-4FC35E76-559E-461E-9B91-BF9D40487363 Q36764809-13DF7542-F273-4B6F-888B-EBC7986062CD Q36902655-48A6FBD0-3DA9-4D6F-AC23-5FF888F5D2C8 Q37046260-3CE23205-703D-44F1-A3B3-8CAEA165B874 Q37209930-6C7E7770-531B-44E3-A292-169E9935553E Q37377220-5822C508-D69C-4385-AE9D-17B1DE8126CB Q37472354-B1D11409-4E50-4701-8BF8-31A62FD7B7E3 Q37632907-0D908ACB-EB85-4BDA-B570-A8BD4A068835 Q38366584-9A39A0BE-2685-4BA8-BC97-2493C24A758C Q38634380-C96B59A1-514B-4944-8530-7F7C9007E18F Q38697221-620F364C-DC9C-45C1-93C2-D49549E63BE0 Q38813514-BAFC6715-9953-4FF9-B5F5-EB325B8D7F9D Q38954546-953CAF30-0EE5-48F9-94A8-D7E611FCF80C Q38966905-78277D91-7BB0-4CF2-8473-6E34E5E339AF Q41647903-02CBF4A2-531D-488C-993F-AF487A54A95B Q42180557-691D6BA6-6B86-4CBB-8EF3-1713F2ED5EB8 Q46262411-FB32F9BB-0CD4-4ECD-A6C2-BB545C2B70C6 Q49209465-FFEDFD1D-CDFD-4B73-9F05-8D3FB042E8BF Q52311728-AD40681B-A1A7-402E-9A00-FFD6986468F1 Q52644448-181BFFE3-9680-407F-93B5-3BAE11047CB9 Q54119547-8F5A0738-CF82-4E4F-98FC-2608C2DC5A3E Q57067876-0EB1F58F-0E89-423C-81C8-45A78DFA65A6 Q57191819-E7002A60-0D02-4D5B-A288-C9AE8D85B6AF Q58700390-3A44BA53-51F7-4985-8DEB-6B0CB9D51938

P2860

A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease

http://www.wikidata.org/entity/Q34070770

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A pilot study of serum microRN ...... nalcoholic fatty liver disease

@ast

A pilot study of serum microRN ...... nalcoholic fatty liver disease

@en

A pilot study of serum microRN ...... nalcoholic fatty liver disease

@nl

type

label

A pilot study of serum microRN ...... nalcoholic fatty liver disease

@ast

A pilot study of serum microRN ...... nalcoholic fatty liver disease

@en

A pilot study of serum microRN ...... nalcoholic fatty liver disease

@nl

prefLabel

A pilot study of serum microRN ...... nalcoholic fatty liver disease

@ast

A pilot study of serum microRN ...... nalcoholic fatty liver disease

@en

A pilot study of serum microRN ...... nalcoholic fatty liver disease

@nl

P1433

Q34070770-1AF2E7FA-48A2-4D4B-9117-56FC2B500D9B

P1476

Q34070770-F19D39DE-44DF-425F-9A4F-B83FC26ABC80

P2093

Q34070770-330A76EB-C572-48E4-838E-E484FB5268A2

Q34070770-3AAC7F55-CC7D-48AF-8218-4C8D5F22E7DF

Q34070770-504FE134-A4FA-40FF-A3E9-2D1A05109DB2

Q34070770-7039C087-B26A-41A2-BEDD-70B40142A300

Q34070770-A0CA4069-0AF9-42B7-90A8-F1B5DE2A0B80

P2860

Q34070770-1034C826-B994-4876-9B89-A1DA5A54DC87

Q34070770-1336B201-9CB9-48CB-B45C-D99A6575A031

Q34070770-18445AF4-1250-42C2-9665-5E3E7624983F

Q34070770-19237EBD-BFAD-49E2-8745-B5DE064B3A8D

Q34070770-1E2D52C3-BF74-4164-98CF-4880B98EA7D4

Q34070770-20595322-C221-4D77-B522-1930B36B7271

Q34070770-25B1A0C6-AD36-40D8-9153-F0295B6DB46D

Q34070770-2D5DBAE4-B7D2-4289-B339-18DF01F97CD7

Q34070770-3E9FFE63-2E34-420E-AE3F-86BAD5BC2476

Q34070770-42B99AFA-E423-4B40-B4BA-44A866576C01

P304

Q34070770-C6F0E90C-1E83-4334-B91C-55232019A45A

P31

Q34070770-24A16310-2B6F-4CDF-883C-2A74B9C9233D

P356

Q34070770-5FF16211-B73A-47A8-91A9-8141A2C8A8B3

P407

Q34070770-9618B340-F0DD-477A-94E6-71953E1B606C

P433

Q34070770-ACEA1E07-CCC0-4C2E-A280-65A7CAC172D0

P478

Q34070770-99CC82FF-C43E-482C-8CB5-AF207CB3366B

P577

Q34070770-A3EBAD62-F2A4-4E87-8CA5-212F180A224E

P5875

Q34070770-F9ACDE58-61C6-4BBE-98B4-C626E6491228

P698

Q34070770-F8BAA89C-4016-45D3-AD1E-7B18CFB1E19A

P921

Q34070770-57E04121-23E2-4596-9A26-DEE6206BDF6D

Q34070770-CB2616C9-A785-4F0C-8794-901A638AB7D2

P932

Q34070770-59EB6EF5-42A2-4EF8-B50A-9DFE1436E808

P356

JOURNAL.PONE.0105192

P1433

P1476

A pilot study of serum microRN ...... nalcoholic fatty liver disease

@en

P2093

Danfeng Wen

http://www.w3.org/2001/XMLSchema#string

Guohong Ge

http://www.w3.org/2001/XMLSchema#string

Jianhe Gan

http://www.w3.org/2001/XMLSchema#string

Tengli Pan

http://www.w3.org/2001/XMLSchema#string

Youwen Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Real-time quantification of microRNAs by stem-loop RT-PCR

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

MicroRNA-192 suppresses liver metastasis of colon cancer.

Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.

Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases.

Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis.

P304

e105192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0105192

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264941356

http://www.w3.org/2001/XMLSchema#string

P698

25141008

http://www.w3.org/2001/XMLSchema#string

P921

P932

4139327

http://www.w3.org/2001/XMLSchema#string